- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07674082
Standard Versus Novel RFA for Chronic Knee Pain in Osteoarthritis
A Prospective Pilot Study Comparing Standard and Novel Radiofrequency Ablation Protocols for Chronic Knee Pain in Osteoarthritis
Brief Summary
The goal of this pilot study is to evaluate the feasibility and safety of conducting a randomized comparison of two standard-of-care knee radiofrequency ablation (RFA) techniques in adults with chronic knee pain related to knee osteoarthritis.
Participants who are already scheduled to receive knee RFA as part of their standard clinical care will be randomized to receive either a standard 3-target (standard) RFA protocol or a 6-target (novel) RFA protocol. The main purpose of this pilot study is to determine whether a future larger randomized trial comparing these two RFA approaches is feasible and safe to conduct.
Participants will complete questionnaires about pain, knee function, and stiffness at baseline and at follow-up timepoints for up to 12 months after the RFA procedure. Preliminary pain relief outcomes will also be explored to help inform the design of a future definitive trial.
Participants already scheduled for a knee RFA procedure as part of their standard of care for pain related to knee osteoarthritis will answer online survey questions about their pain for up to 12 months.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
This is a prospective, longitudinal, single-centre randomized pilot study with follow-up to 12 months. Participants scheduled to receive standard-of-care knee RFA for chronic knee pain related to osteoarthritis will be randomized through REDCap in a 1:1 manner to receive either the standard 3-target RFA protocol or the novel 6-target RFA protocol.
In usual clinical care, the RFA technique would typically be selected by the treating physician and both techniques are being done as standard of care. In this study, assignment to one of the two RFA techniques will be randomized. The RFA procedure itself will be completed as part of standard clinical care.
Study-related activities include randomization, collection of limited demographic and clinical information from the medical record, collection of procedural information, adverse event monitoring, and participant-reported outcome assessments. Outcomes will be collected at baseline before the procedure and at 3, 6, 9, and 12 months post-procedure. Follow-up may be discontinued at or after 6 months if the participant's pain returns to baseline levels or if the participant undergoes a repeat procedure.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Melissa Calleja, MSc
- Numero di telefono: 42208 519-646-6100
- Email: melissa.calleja@sjhc.london.on.ca
Backup dei contatti dello studio
- Nome: Arden Lawson, MSc
- Numero di telefono: 42570 519-646-6100
- Email: arden.lawson@sjhc.london.on.ca
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Any patient with knee osteoarthritis receiving knee RFA.
- Stable pain medications for past 1 month.
- Able to speak English.
Exclusion Criteria:
- Scheduled for knee surgery within 6 months following RFA procedure.
- Participating in another study that the Principal Investigator or Co-Investigators deem will interfere with the interpretation of the results.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Traditional RFA
Participants randomized to this arm will receive the standard 3-target knee RFA protocol as part of their standard clinical care.
|
X-ray imaging is used to guide needles that target the superior lateral, superior medial, and inferior medial genicular nerves surrounding the knee, heat is used to ablate the nerves.
|
|
Comparatore attivo: Novel RFA
Participants randomized to this arm will receive the 6-target knee RFA protocol as part of their standard clinical care.
|
X-ray imaging is used to guide needle placement for radiofrequency ablation targeting the superior lateral, superior medial, and inferior medial genicular nerve regions around the knee.
The 6-target protocol also includes supplementary ablation lesions at three additional target sites around the knee.
These additional targets are treated by adjusting the needle angle once inserted, without requiring additional needle insertions beyond the standard approach.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Nature of adverse events
Lasso di tempo: up to 12 months
|
The types of adverse events occurring while participants are in the study will be reviewed.
|
up to 12 months
|
|
Frequency of adverse events
Lasso di tempo: up to 12 months
|
defined by the number of adverse events a participant experiences while participating in the study
|
up to 12 months
|
|
Recruitment rate
Lasso di tempo: During enrolment period
|
Average number of participants enrolled per month during the recruitment period.
|
During enrolment period
|
|
Retention and Attrition Rates
Lasso di tempo: 3, 6, 9, and 12 months post-procedure
|
proportion of participants retained and the proportion lost to follow-up at each scheduled follow-up timepoint
|
3, 6, 9, and 12 months post-procedure
|
|
Questionnaire Completion Rate
Lasso di tempo: Baseline, 3, 6, 9, and 12 months post-procedure
|
completion rates for the Patient Numeric Rating Scale (PNRS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaires at each scheduled study timepoint.
|
Baseline, 3, 6, 9, and 12 months post-procedure
|
|
Procedural efficiency
Lasso di tempo: Baseline
|
total procedure duration, measured from needle placement to final lesion completion.
The 6-target protocol will be compared with the 3-target protocol to determine whether it adds no more than 20 minutes on average and remains within the 60-minute operating room threshold.
|
Baseline
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Average time to return to <50% pain relief
Lasso di tempo: Baseline, as well as 3-, 6-, 9-, and 12-months post-procedure
|
Measured by the pain numeric rating scale, where zero is equivalent to no pain and 10 indicates the worst possible pain
|
Baseline, as well as 3-, 6-, 9-, and 12-months post-procedure
|
|
Average time to return to baseline pain level
Lasso di tempo: baseline, 3 months, 6 months, 9 months and 12 months post procedure
|
Measured by the pain numeric rating scale (PNRS), where 0 indicates no pain, and 10 indicates worst imaginable pain.
|
baseline, 3 months, 6 months, 9 months and 12 months post procedure
|
|
Change in functional outcomes
Lasso di tempo: Baseline, as well as 3-, 6-, 9-, and 12-months post-procedure on the following questionnaires.
|
Measured by the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index, a patient-reported questionnaire assessing pain, stiffness, and physical function.
Total scores range from 0 to 96, with higher scores indicating worse symptoms and greater functional limitation.
|
Baseline, as well as 3-, 6-, 9-, and 12-months post-procedure on the following questionnaires.
|
Collaboratori e investigatori
Investigatori
- Cattedra di studio: Eldon Loh, MD, Lawson Health Research Institute of St. Joseph's
- Investigatore principale: John Tran, PhD, Lawson Health Research Institute of St. Joseph's
Pubblicazioni e link utili
Pubblicazioni generali
- Julious, S.A. (2005), Sample size of 12 per group rule of thumb for a pilot study. Pharmaceut. Statist., 4: 287-291. https://doi.org/10.1002/pst.185
- Tran J, McCormick ZL, Lanting BA, Lisk K, Loh E. Patient-specific knee radiofrequency ablation using contrast spread analysis and 3D anatomy knowledge: teaching Images. Pain Med. 2026 Mar 1;27(3):370-373. doi: 10.1093/pm/pnaf137. No abstract available.
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- JTNRFA001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Artrosi, ginocchio
-
University of GroningenCompletato
Prove cliniche su Radiofrequency ablation - 3-target technique
-
Ultra Botanica LLCAttivo, non reclutanteDisagio articolare | Qualità della vita (QOL)Stati Uniti
-
Centre Cardiologique du NordNon ancora reclutamentoDelirio postoperatorio | Profondità anesteticaFrancia
-
University of ArizonaAmgenCompletatoCancro della pelle | Carcinoma spinocellulare | Cheratoacantoma | Tumore cutaneo | Cancro della pelle, cellule squamose | Pelle di lesioneStati Uniti
-
Xiayun He, MDCompletato
-
Roswell Park Cancer InstituteSospesoCarcinoma epatocellulare avanzato | Carcinoma epatocellulare ricorrente | Carcinoma epatocellulare in stadio III AJCC v8 | Carcinoma epatocellulare in stadio IV AJCC v8 | Carcinoma epatocellulare refrattario | Carcinoma epatocellulare metastaticoStati Uniti